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A B S T R A C T
Bioequivalence (BE) assessment of topical dermatological products is a long standing
challenge. The development of generic topical dermatological products has often been
hampered due to the limited number of acceptable approaches, which are capable of
determining the BE between generic products and reference list products. The aim of this
manuscript is to review different BE assessment approaches of topical dermatological
products. Besides, the advances in BE evaluation and biowaivers are also provided. Cur-
rently, except in the case of dermatological corticosteroids, the golden rule to establish the
BE of most topical dermatological products still heavily relied on clinical endpoint trials,
which are often unreliable, time-consuming and expensive. The regulatory agencies and
pharmaceutical industries are forging ahead to the development of new surrogate BE
assessment approaches for other topical dermatological products. These promising ap-
proaches include dermatopharmacokinetic study (DPK), dermal microdialysis (DMD), in
vitro studies, pharmacokinetic study (PK), near-infrared spectrometry (NIR), and confocal
Raman spectroscopy (CRS). In addition, the expansion of biowaivers for topical dermato-
logical products has been explored by pharmaceutical scientists. In conclusion, to accelerate
the development and approval of topical dermatological products, emphasis should be
put on the following areas, i.e., optimizing and standardizing the existing BE assessment
methods, exploring novel alternatives of BE assessment approaches, and expanding biowaivers
for topical dermatological products.
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is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Generally, when a new generic product becomes available in
the market, the competition of generic pharmaceutical indus-
try is felt immediately, and as a result, the prices of both
reference list products (RLDs) and generic dosage forms reduce
substantially. However, for topical dermatological products, the
competition of generic industry remains limited despite the
expiration of all exclusive protections of the RLD.This is mainly
attributed to the limited number of acceptable BE assess-
ment approaches to demonstrate the BE between generic topical
dermatological products and RLDs [1].
As with all types of generic products, regulatory agencies
require the demonstration of therapeutic equivalence to its
corresponding RLD, which includes the confirmation of phar-
maceutical equivalence and BE [2]. As stated in 21 CFR 314.94
[3], pharmaceutical equivalence means that the generic product
must have the same active ingredient in the same strength,
and it must be the same dosage form and uses the same route
of administration as its RLD. Besides, the inactive ingredients
in the generic dosage form should be qualitatively the same
and quantitatively similar (±5%) compared with its RLD. In ad-
dition, according to a guideline in 21 CFR 320.24 [3], BE is defined
as “the absence of a significant difference in the rate and extent
to which the active ingredient or active moiety in pharma-
ceutical equivalents become available at the site of action when
administered at the same molar dose and under similar
conditions in an appropriately designed study.” From both
regulatory and clinical standpoints, it is crucial to perform BE
evaluation study to ensure that the generic formulation is thera-
peutically equivalent to its RLD.
However, determination of topical BE for locally acting drugs
in skin is more complicated than solid dosage forms. In
contrast to orally administered products, most topical derma-
tological products are meant to be locally active, which provide
limited systemic absorption, thus precluding the application
of common procedures for BE determination of orally admin-
istered products (i.e., measuring the rate and extent of drug
absorbed in plasma). The demonstration of BE between a
generic topical dermatological products and its RLD is a long
standing challenge for the lack of accepted bioequivalence
methods. Currently, clinical end-point trials are still the only
gold standard to establish BE for most generic topical derma-
tological products, except for dermatological corticosteroids,
which are determined via specific pharmacodynamic tests rec-
ommended by FDA [4].The clinical end-point trials are generally
lengthy, expensive and entail a large patient population. Phar-
macodynamic study requires a relatively small number of
subjects and is easier to perform, but it is constrained to der-
matological corticosteroids [4]. Therefore, considerable effort
has been directed to address this situation, and to find alter-
native BE assessment approaches for topical dermatological
products. These promising surrogate approaches, including
dermatopharmacokinetic study (DPK), dermal microdialysis
(DMD), in vitro studies, near-infrared spectroscopy (NIR), and
confocal Raman spectroscopy (CRS) [5–9], are under consider-
ation as potential strategies to establish BE for topical
dermatological products by pharmaceutical scientists and der-
matologists.Among these alternatives, DPK, DMD, in vitro studies
and NIR are critical opportunity pathways identified by the FDA
[1]. Other methods, such as suction blister and skin biopsy, have
been applied to determine cutaneous drug concentration in
human skin, but these methods are unsuitable to human
subjects due to their aggressive nature, which may cause per-
manent scarring [10,11].Approaches for BE assessment of topical
dermatological products are summarized in Fig. 1.
This short review mainly focuses on several promising sur-
rogate approaches to demonstrate the BE of generic topical
dermatological products and their recent advances in this area.
Approaches for BE assessment of topical dermatological products 
Acceptable 
Clinical 
Pharmacodynamic 
Promising 
DPK 
DMD 
PK 
In vitro 
NIR 
CRS 
Unacceptable 
Suction Blister 
Skin Biopsy 
Fig. 1 – Approaches for BE assessment of topical dermatological products.
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Besides, a summary of the advance in biowaiver from BE as-
sessment is also provided.
2. Acceptable approaches for BE assessment
of topical dermatological products
2.1. Clinical endpoint trials
For most topical drug products, clinical endpoint trial is used
to demonstrate BE between the generic product and its RLD.
Even though it provides clinicians with a chance to directly
evaluate the generic products, this method is the least sensi-
tive and reproducible among all general approaches to
demonstrate BE [3]. Besides, clinical endpoint trial is often
costly, time-consuming, difficult to conduct, and entails large
patient population [12]. The FDA has acknowledged the need
to find more sensitive and more efficient surrogate ap-
proaches to demonstrate BE for topical dermatological products.
Generally, for a specific new generic topical drug product,
FDA will provide sponsors with product-specific clinical rec-
ommendations or consider whether a biowaiver is appropriate.
If BE recommendation from FDA is not available or the spon-
sors prefer other rational alternative methods, the sponsors
need to provide sufficient data to convince the FDA on using
such method to demonstrate BE between the generic product
and its RLD [13].
2.2. Pharmacodynamic study
The only accepted surrogate method to clinical trial by several
regulatory agencies (especially FDA) is pharmacodynamic study.
The approach is based on the vasoconstriction activity of der-
matological corticosteroids to produce skin blanching at the
site of application [14]. The intensity of skin blanching, corre-
lating with drug potency, is measured by a chromameter at
various time points [15]. Pharmacodynamic study is much
simpler and involves less patient population than clinical end-
point trials. However, several issues have been identified
previously. One of the most common issues is high inter-
subject variability, which requires a relatively larger number
of subjects than DPK and DMD methods [12]. Moreover, a pilot
study must be performed to determine the dose duration and
to select responders (subjects with confirmed adequate vaso-
constriction) [4]. Moreover, the design of pilot test may influence
the results of pivotal test [16].Therefore, the original FDA guide-
line has undergone several refinements, such as reducing
sampling times, conducting a cleaning procedure before the
test, and investigating the integration of stratum corneum (SC)
[12].
In addition to the vasoconstriction effects of dermatologi-
cal corticosteroids, other pharmacodynamic responses have also
been reported. For instance, the vasodilatation effect of topical
NSAIDs caused by nicotinic acid can be used to evaluate the
absorption of topical NSAIDs by a laser Doppler velocimeter
[17,18]. In addition, application of transepidermal water loss
(TEWL) effect in assessing the absorption of topical retinoids
has also been reported [19,20].
3. Promising alternative BE assessment
approaches of topical dermatological products
3.1. Dermatopharmacokinetic study (DPK)
The application of pharmacokinetics in drug concentrationmea-
surement in SC is termed as dermatopharmacokinetics, which
is known as tape stripping. The rationale behind DPK ap-
proach is that the determination of drug concentration in SC
reflects the BE evaluation between a generic product and its
RLD, since topical dermatological products are skin targeting
[21]. FDA issued a draft guideline on this method to establish
BE for all topical formulations in 1998 [22]. A comparative BE
evaluation of two commercially available tretinoin gel prod-
ucts was later conducted via DPK method in two different
laboratories, but their results were contradictory from each
other, which led to a withdrawal of the proposed draft guide-
line in 2002 [23]. The reason of the withdrawal was that these
two studies were performed based on inconsistent protocols.
Considerable effort has been made by the FDA and other labo-
ratories to analyze the source of variability and refine the
original DPK study. The refinements emphasized that DPK
procedure must be standardized. More specifically, the
transepidermal water loss (TEWL) was involved in the test to
ensure a complete removal of SC. A smaller stripping area was
adopted to avoid edge effects. Measurements were dupli-
cated to reduce intra-subject variability, and the number of
sampling times were decreased to obtain lesser degree of vari-
ability [24]. In addition, a recent study proposed that the total
SC removal area should be determined to maintain uniform
SC thickness [25].
Although modifications have been made, there are still
several limitations in DPK study. First, it is only valid for drugs
whose target organ is SC, but SC is usually not the therapeu-
tic target [26]. Besides, this technique is only applicable to
healthy skin and has to be standardized when the site of action
is a diseased skin [8]. Furthermore, DPK is associated with nu-
merous variables that may lead to inter- and intra-lab variation
[27]. Finally, it is noteworthy that DPK is invasive to a certain
degree when considering the skin irritation caused by com-
plete removal of SC.
However, DPK approach has been considered as a promis-
ing option for establishing the BE of topical dermatological
products. DPK was proved to be less variable between differ-
ent subjects than pharmacodynamic study, and superior to in
vitro tests in differentiating different strengths of triamcino-
lone acetonide [28]. The most important advantage of DPK
approach is that both the generic product and the original one
are evaluated in the same subject, thus reducing inter-subject
variability and the number of subjects [29]. Parfitt et al. [30] de-
termined the BE between 1% generic clotrimazole cream and
its RLD by using a revised DPK method.The data strongly sup-
ported that DPK has necessary attributes and potentials for the
BE assessment of topical formulations. N’Dri-Stempfer et al.
[29] reported an improved BE evaluation method to assess 1%
econazole creams whose site of action is SC. Their results in-
dicated that a robust BE assessment approach with higher
sensitivity was obtained by adopting modifications, namely
using TEWL to measure the fraction of SC, performing a new
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cleaning procedure to reduce variability, and involving all tape
strips for the comparison. Pershing et al. [27] explored the fea-
sibility of using DPK approach to demonstrate BE of three types
of tretinoin gels by comparing with the corresponding clini-
cal data. The results confirmed the clinical relevance of DPK
approach and supported its use in the BE assessment of topical
dermatological products.
3.2. Dermal microdialysis (DMD)
Dermal microdialysis is a technique for real-time measure-
ment of the rate and extent of drug penetration into the skin.
It is capable of determining the target-site concentration of
drugs in almost all human tissues via in vivo sampling of en-
dogenous and exogenous substances in the extracellular fluid
[31–33]. One of the most important advantages of DMD is its
capacity to measure topical drugs penetrating across both
healthy and diseased skins [34,35]. However, DMD has limita-
tions in the case of lipophilic protein-bound and high-molecular
weight drugs, which are ascribed to membrane binding and/
or size exclusion [36–38]. Besides, DMD is a relatively invasive
procedure which may cause transient inflammation [39,40].
Moreover, it is necessary to use associated markers for drug
concentration determination [41].
Nevertheless, DMD is viewed as a potential strategy to
analyze the BE of generic topical dermatological products by
regulatory agencies [42]. Recently, studies concerning its ap-
plication in evaluation of BE for topical products have been
discussed. According to Brunner et al. [43], the BE of five topical
diclofenac formulations was analyzed by DMD. Four diclofenac
formulations showed 2.71 times greater AUC and approxi-
mately 30–40 times faster penetration rate compared with their
commercial counterpart. Another example to corroborate the
feasibility of using DMD in BE establishment of topical prod-
ucts was performed by Tettey-Amlalo et al. [44] in a study that
assessed the BE of ketoprofen topical gels by comparing AUC
of the generic product and its RLD. As a result, BE was dem-
onstrated with a power greater than 90% and intra-subject
variability lower than 10%, which provided a compelling evi-
dence for DMD to be used as a promising alternative for clinical
trial.
3.3. In vitro study
In vitro study involves the measurement of drug release from
base to receptor cell by using a vertical diffusion system sepa-
rated by the excised skin or a synthetic membrane [45]. The
excised skin was used to model the lipid perturbation effects
and study drug diffusion from transdermal products [46]. The
main limitation of excised skin is the high degree of variabil-
ity,whichmust be standardized before use. Synthetic membrane
has no lipid perturbation effects, but it is preferred by many
researchers because it is easily resourced, less expensive, and
structurally simple [47].
In vitro drug release is sensitive to several physical and
chemical parameters, such as drug solubility, particle size, and
the arrangement and rheological property of semisolid dosage
forms [48]. In addition, in vitro release test is easier to be carried
out than in vivo test, and also gives insights into drug perme-
ation mechanism. However, there are still concerns about the
method, such as sufficient quality and quantity of the skin,
equivalence of skins from different provision, and standard-
ization of this method [49]. Nevertheless, in vitro study with a
synthetic membrane is accepted as a valuable quality control
tool to ensure product sameness under Scale-up and Post Ap-
proval changes (SUPAC), which include minor changes in
composition, manufacturing process and equipment, site of
manufacture, and scale-up and scale-down of manufacture [50].
Recently, FDA issued a draft guideline regarding an in vitro option
to demonstrate BE for acyclovir ointment [51]. This advance-
ment is deemed as a new initiative of BE assessment by the
FDA, i.e., relying on physicochemical evaluation and in vitro
release test. Specifically, there are several considerations from
the FDA about BE assessment of acyclovir ointment: (i) generic
products must be qualitatively (Q1) and quantitatively (Q2)
equivalent; (ii) generic product and its RLD are microstructurally
same (Q3) in in vitro tests, which means that the compari-
sons of release rates, morphic form, particle size, viscosity, and
molecular weight distribution need to be performed; (iii) if prod-
ucts are not Q1 and Q2 equivalent, clinical endpoint trial is
required [51].
Furthermore, comprehensive studies using in vitro test to
determine BE of topical dermatological products have been per-
formed in recent decades. Franz et al. [52] compared seven
approved generic topical drug products with their correspond-
ing RLD using Franz diffusion cell. The results suggested that
six out of seven cases are in good agreement with clinical data,
which confirmed the predictive power of the in vitro study, and
its usefulness in in vivo BE studies. In another study, Lehman
and Franz [53] demonstrated the BE of dermatological corti-
costeroids by applying in vitro permeation test with
cryopreserved human skin and compared with vasoconstric-
tor assay.The results showed that in vitro test wasmore sensitive
and less variable than pharmacodynamic study in assessing
clobetasol bioavailability, which supported the application of
in vitro test in determining BE of certain topical products. More
importantly, to the best of our knowledge, there is no evi-
dence suggesting that the use of in vitro study compromises
the quality of topical products. Taken together, in vitro study
is one of the most promising approaches to investigate the BE
issue of generic products.
3.4. Pharmacokinetic study (PK)
The FDA issued a draft guideline for generic lidocaine patches
in 2006, which involved pharmacokinetic approach in BE es-
tablishment [54].The feasibility is based on the following facts:
the plasma level of lidocaine is proportional to its presence at
the site of action, and it is feasible to measure lidocaine in
plasma. Therefore, in some special cases of topical dermato-
logical products, where the systemic absorption is significant
and the drug level in plasma is in line with its presence at target
organ, PK studymay be adopted to determine their BE. However,
it has to be noted that PK study is mainly applied to deter-
mine the safety of topical formulations, and its application in
BE assessment is limited.
3.5. Spectroscopy studies
As mentioned above, DPK and MDM approaches are invasive
in some degree. Besides, DPK has an obvious weakness, i.e. the
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tested drug continues to diffuse in the course of tape strip-
ping. As a result, some critical information may be lost during
the test [55].Thus, it is necessary to develop a noninvasive and
rapid approach to assess the BE of topical dermatological prod-
ucts. Spectroscopy study seems to be the best solution in terms
of safety, time, and ease of application. Near-infrared spec-
trometry (NIR) and confocal Raman spectroscopy (CRS) are two
major advanced noninvasive in vivo approaches for real-time
monitoring of drug penetration across the skin [56–58]. However,
both NIR and CRS require that the molecule of interest should
possess distinct spectral peaks with sufficient intensity [59,60].
3.5.1. Near-infrared spectrometry (NIR)
Near-infrared spectrometry represents a relatively novel in vivo
approach for noninvasive assessment of chemicals’ perme-
ation across the skin. NIR wave is capable of penetrating the
skin to a depth of several centimeters. Thus, by measuring IR
spectrum and combining with linear multivariate statistics, the
drug diffusion through skin can be quantified [61]. NIR is su-
perior to other methods due to its nondestructive, rapid, simple
(without sample preparation), and quantitative properties, there-
fore the possibility of drug diffusion during scanning process
can be eliminated, which is favorable for the analysis of vola-
tile drugs. In addition, some NIR approaches are capable
of real-time monitoring the rate and quantity of chemical pen-
etration through the skin [61]. For these reasons, Medendorp
et al. [62] explored the feasibility of using NIR for in vitro quan-
tification of the dermal absorption of econazole nitrate and
4-cyanophenol in guinea pig skin. The results suggested that
NIR needs further exploration for rapid and accurate BE evalu-
ation of topical dermatological dosage forms. Egawa [63] used
in vivo NIR to quantify urea and water contents in human SC
via fiber-optic probes after using urea-containing cream.Their
results indicated that it is possible to involve NIR in in vivo
studies. To sum up, NIR is a new method that is still being ex-
plored, and its use in BE evaluation needs to be further
confirmed.
3.5.2. Confocal Raman spectroscopy (CRS)
Confocal Raman spectroscopy has been widely used in the de-
termination of SC thickness, water content in SC, and effect
of percutaneous penetration enhancers [64–66]. The principle
behind CRS is as follows: a laser beam is focused and di-
rected on the skin by amicroscope objective, and scattered light
is directed through a notch filter and then focused by the same
microscope objective. After that, the light is focused onto an
optical fiber to obtain the spectrograph [67]. Like NIR, CRS is
an advanced completely noninvasive and rapid approach,which
provides real-time in vivo signal to measure the penetration
of chemicals through skin [68]. However, a major drawback of
CRS lies on the fact that it is a semi-quantitative tool that only
provides relative drug concentration rather than an absolute
one [60].
CRS has been applied to measure the rate and extent of di-
methyl sulphoxide into and across the skin. Recently, several
proof-of-concept studies regarding the use of CRS in real-
time drug concentrationmonitoring in skin have been reported.
Mateus et al. [69] explored the use of CRS in in vivo profiling
the deposit of ibuprofen in skin. The study suggested that the
CRS results were in good accordance with the previously pub-
lished data [70] from tape stripping studies and proposed CRS
as a valid approach to measure drug concentration in the SC
for topical products. More recently, Mateus et al. further ex-
plored the relationship between the cumulative amounts of
salicylic acid permeated in vitro and the CRS intensity in skin.
The results provided further confidence in using CRS for drug
deposit determination in skin [9]. Mohammed et al. [71] com-
pared the in vitro permeation of niacinamide from seven
different vehicles with the in vivo uptake of niacinamide in
human skin.The results showed that the Raman signal of nia-
cinamide was directly proportional to the amount of
niacinamide permeating through skin in vitro.The results further
supported the use of CRS to monitor drug penetration through
the skin.
Taken together, although NIR and CRS are novel and at-
tractive techniques due to their nondestructive nature, the
development of both techniques are still on the horizon, and
their future applications in BE assessment are yet to be proved.
However, it can be imagined that these two techniques will open
a new avenue for research when their application in BE es-
tablishment is further validated.
4. Waiver from BE study for topical
dermatological products
For topical dermatological solutions, the FDAwill consider grant-
ing biowaivers, provided that the generic topical dermatological
product fulfils the following requirements: (i) it is a solution;
(ii) it contains the same active ingredient in the same con-
centration and dosage form; (iii) and it does not contain other
ingredients or change in formulation that may significantly
affect drug availability [72]. Besides, considerable effort has been
made by pharmaceutical scientists to explore the possibility
of expanding biowaivers for topical dermatological products.
Shah et al. [2] recommended that it is possible to consider
biowaivers for topical dosage forms with lower strengths at the
following conditions: (i) an in vivo BE between the generic
product with higher strength and its RLD has been demon-
strated, (ii) the generic product with lower strength has drug
amount proportional or pseudo-proportional to its RLD, and
(iii) similar drug release profiles have been demonstrated for
generic product with the highest strength and its RLD. This
proposal is based on the case of oral solid dosage forms
with multiple strengths, where biowaivers are granted for
lower strengths by the FDA, when the highest strength is
bioequivalent; the lower strengths are proportional or pseudo-
proportional, and have similar drug release profiles compared
with the highest strength of the bioequivalent product [73]. In
addition, in light of Biopharmaceutics Classification System
(BCS) for oral solid dosage forms, which is based on sound sci-
entific principles and has led to great success in promoting the
development of generic oral solid products, the authors further
proposed aTopical Drug Classification System (TCS) for topical
products [2].The proposedTCS is based on qualitative (Q1) and
quantitative (Q2) equivalence of composition, and the simi-
larity of in vitro release rates (an estimator of microstructural
consistency; Q3) between a generic topical product and its RLD.
If the generic topical product has the same Q1 and Q2, and
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meets Q3 comparison requirements identified in SUPAC-SS [50],
it will be classified asTCS class 1. If the generic topical product
has the same Q1 and Q2, but is different in Q3, it will be clas-
sified as TCS class 2. If the product has different Q1 and Q2,
but meets Q3, for example when the excipients are inert and
have no significant impact on in vitro release rate, it can be clas-
sified as TCS class 3. Lastly, if Q1, Q2, and Q3 of the product
are all different, the generic topical product will be classified
asTCS class 4.The general classification of topical dosage forms
based on TCS is shown in Fig. 2. Under the classification, only
for TCS class 1 and TCS class 3 dosage forms, a biowaiver can
be allowed. TCS class 2 and TCS class 4 are not eligible for
biowaiver, for which the in vivo BE studies are required.
To sum up,TCS is proposed based on the composition and
physicochemical properties of topical products, and uses in vitro
release test as a tool to control product quality. TCS is indeed
an extension of SUPAC-SS in the application of in vitro release
rate. It is envisaged that if TCS for topical dosage forms is ac-
cepted by regulatory agencies, the unnecessary in vivo study
will be eliminated and the regulatory burden will be reduced.
Additionally, it may substantially facilitate the development
and approval of generic topical dermatological products. Con-
sequently,more topical drug products with reasonable cost will
be available to the patients.
5. Conclusion
In this review, we have discussed several promising alterna-
tive BE assessment approaches of topical dermatological
products and their recent progress. Besides, a summary of the
progress of biowaiver in this area is also provided. Because each
BE assessment approach has its own merits and limitations,
an integration of multiple approaches can be adopted to fa-
cilitate a successful BE determination between topical generic
product and the corresponding RLD. Just as pharmaceutical sci-
entists and dermatologists have stressed, “whole toolkit” of
approaches should be adopted to demonstrate the BE of topical
dermatological products [12,74].
The future emphasis of BE assessment for topical derma-
tological products would be directed toward the refinement and
standardization of the existing approaches, development of new
alternative BE approaches, establishment of detail guideline
for each method by FDA, and the exploration of expanding
biowaivers of topical dermatological products [8,75]. To tackle
these tough tasks, academicians, pharmaceutical industry, and
regulatory agencies need long-term plans and cooperation. It
is hoped that their collaborative endeavors will boost the de-
velopment of robust BE assessment approaches and facilitate
the development, registration, and ultimate approval of topical
dermatological products.
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